Form 4: PMV Pharmaceuticals CFO Acquires 265,000 Employee Stock Options
SEC Filing
Michael Carulli, CFO of PMV Pharmaceuticals, acquired 265,000 employee stock options on March 3, 2025, according to a Form 4 filing.
Summary
- Michael Carulli, the Chief Financial Officer of PMV Pharmaceuticals, Inc. (PMVP), acquired 265,000 employee stock options on March 3, 2025.
- The options have an exercise price of $1.32.
- The options vest in 48 equal monthly installments starting on April 3, 2025.
- The options expire on March 3, 2035.
- The acquisition was reported on a Form 4 filing with the SEC on March 5, 2025.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing regarding stock option grants, which is neither particularly positive nor negative.
Future Outlook
The document does not contain any specific forward-looking statements or guidance.
Industry Context
Form 4 filings are routine disclosures related to insider transactions and are a standard part of regulatory compliance for publicly traded companies.
Stakeholder Impact
- The acquisition of stock options by the CFO aligns his interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 03/03/2025 | Date of the transaction: CFO acquired employee stock options. |
| 04/03/2025 | First vesting date for the acquired stock options. |
| 03/05/2025 | Date of Form 4 filing. |
| 03/03/2035 | Expiration date of the acquired stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.